Common Contracts
4 similar Employment Agreement contracts by Mana Capital Acquisition Corp.
EMPLOYMENT AGREEMENTEmployment Agreement • August 23rd, 2022 • Mana Capital Acquisition Corp. • In vitro & in vivo diagnostic substances • Illinois
THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of May 27, 2022, by and between Cardio Diagnostics, Inc., a Delaware corporation (the “Company”), and Robert Philibert, (the “Executive” and together with the Company referred to as the “Parties”). For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:
EMPLOYMENT AGREEMENTEmployment Agreement • August 23rd, 2022 • Mana Capital Acquisition Corp. • In vitro & in vivo diagnostic substances • Illinois
THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of May 27, 2022, by and between Cardio Diagnostics, Inc., a Delaware corporation (the “Company”), and Timur Dogan (the “Executive” and together with the Company referred to as the “Parties”). For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:
EMPLOYMENT AGREEMENTEmployment Agreement • August 23rd, 2022 • Mana Capital Acquisition Corp. • In vitro & in vivo diagnostic substances • Illinois
THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of May 27, 2022, by and between Cardio Diagnostics, Inc., a Delaware corporation (the “Company”), and Elisa Luqman (the “Executive” and together with the Company referred to as the “Parties”). For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:
EMPLOYMENT AGREEMENTEmployment Agreement • August 23rd, 2022 • Mana Capital Acquisition Corp. • In vitro & in vivo diagnostic substances • Illinois
THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of May 27, 2022, by and between Cardio Diagnostics, Inc., a Delaware corporation (the “Company”), and Meeshanthini Dogan, (the “Executive” and together with the Company referred to as the “Parties”). For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:
